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Objective This study highlights the protective effects of montelukast on myocardial ischemic reperfusion injury induced by cardiopulmonary 
bypass during valve replacement surgery. 
Methods A total of 60 patients with valvular disease undergoing elective valve surgery were enrolled in this randomized single-blinded study. 
Participants were divided into two main groups: Montelukast-treated group consisted of 30 patients who were given 10 mg montelukast sodium 
(Singulair®, MSD, USA) tablet, once daily at bedtime for 3 days before valve surgery. Control group consisted of 30 patients who underwent valve 
surgery without taking montelukast tablets. Blood samples were collected at following times (T0; T1 before aortic cross clamp; T2 after aortic cross 
clamp; and T3 24 h after the surgery), for measuring several inflammatory markers. Ejection fraction (EF) was measured before surgery and three 
months after surgery. Pulmonary functions were measured before and after the surgery in both study groups. 
Results There were significant increase in the levels of TNF-a, IL-6, a2 macroglobulin/creatinine ratio and CTnI, in the control group 
compared to the montelukast-treated group among different study times, (P < 0.05). In addition, the EF was significantly higher in the 
montelukast-treated group after the valve surgery, (P < 0.05). Levels of forced vital capacity (FVC), forced expiratory volume 1 (FEV1), and 
FEV1/FVC ratio where significantly higher in the montelukast-treated group than the control group, (P < 0.05). 
Conclusion This study shows the benefits of using pre-surgical montelukast supplement in ameliorating the inflammatory process in 
patients undergoing cardiopulmonary bypass during valve replacement surgery.
Keywords montelukast, mitral and aortic valve replacement surgery, ischemia reperfusion injury, interleukin-6, cardiac troponin 1, tumor 
necrotic factor-alpha, alpha 2 macroglobulin/creatinine, ejection fraction, forced vital capacity (FVC), forced expiratory volume in one 
second (FEV1), FEV1/FVC ratio
Introduction
Cardiopulmonary bypass (CPB) is an important procedure, 
which is routinely performed as part of a classical cardiac surgery 
and support of life,1 but it is associated with injury that may 
induce pathological changes in the form of systemic inflamma-
tory response syndrome (SIRS) or multiple organ dysfunction 
syndrome (MODS).2 SIRS remains as a distress in open-heart 
surgery, and lack of adequate patient screening is an ongoing 
problem.3,4 It is particularly noteworthy that SIRS is initiated by 
many factors including surgical trauma, reperfusion of ischemic 
organ and CPB.4 The CPB is the major factor for initiating SIRS 
since off-pump cardiac surgery has been shown to significantly 
reduce inflammatory response.5,6 Other related factors triggering 
the inflammatory response including hemodilution; electrolyte 
imbalance; pharmacological agents which are used during sur-
gery; myocardial cardioplegic arrest; formation of heparin– 
protamine complex; and the release of endothelin and the 
expression of adhesion molecule on leukocyte and endothe-
lium.5,6 There are evidences supporting that CPB can induce 
the activation of most of the body’s major host defensive pro-
cesses, include the activation of various complements, coagula-
tion factors, kinins, fibrinolysis, leukocytes, platelets and 
inflammatory cytokines.7 This study aims to evaluate the possible 
protective effects of montelukast as a selective cystienyl leukot-
riene-1 receptor antagonist in the myocardial ischemic reperfu-
sion injury induced by heart valve replacement surgery.
Patients and Methods
Sixty patients (23 males and 37 females) with valvular heart 
disease undergoing elective valve surgery were randomly 
included in this single-blinded clinical trial. The study was 
conducted at the Cardiothoracic Center, Al Sadir Medical 
City, Najaf, Iraq between April 2015 and December 2016. Par-
ticipants were classified into two main study groups:
Group 1
Montelukast-treated group (MK group) included 30 patients 
who underwent valve surgery (14 patients had a mitral valve 
replacement, MVR) and (16 patients had an aortic valve 
replacement, AVR). Participants in this group were given 
10 mg montelukast sodium (Singulair®, MSD, USA) tablet, 
once daily at bed time for 3 days before valve surgery.8,9 
Group 2 
(Control group, C group) included 30 participants who 
underwent valve replacement surgery (17 patients had a 
mitral valve replacement, MVR) and (13 patients had an 
aortic valve replacement, AVR). Participants in this group 
had no montelukast supplement, and they were considered 
as controls. 
Blood samples were collected at following times, 
(T0 after anesthesia; T1 before aortic cross clamp; T2 after 
aortic cross clamp; T3 24 h after the valve replacement 
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surgery), for the measurements of the following inflamma-
tory biomarkers (tumer necrotic factor alpha (TNF-a); 
Interleukin 6 (IL-6); Alpha 2 macroglobumin over creati-
nine (a2 macroglobulin/creatinine) ratio and cardiac tro-
ponin 1 (cTnI). For all participants, serum samples were 
separated and stored at −80°C until analysis. The determi-
nation of cytokines was formed using an ELISA assay 
(Cloud-Clone Corp., USA). 
Bronchial wash was collected from each participants before 
the valve replacement surgery and after the completion of the 
operation in order to determine the levels of IL6 and TNFa. 
Echocardiography was also performed to determine the 
ejection fraction (EF) before the surgery and was repeated 
three months after the surgery. 
Pulmonary function test was undertaken 2 days before 
the surgery and 10 days after the surgery in order to evaluate 
the lung protective effects of montelukast in non-asthmatic 
participants to determine the levels of the forced vital capacity 
(FVC); forced expiratory volume 1 (FEV 1); and the FEV 1/FVC 
ratio as measured by Spirometer.
Statistical Analysis
Data were analyzed to determine the mean and standard error 
of the mean using statistical package for social sciences (SPSS) 
version 20 software for windows. The study used independent 
sample t-test, paired t-test and chi-squared test for categorical 
variables. A P-value of ≤0.05 was considered significant.
Results
Participants of the two study groups were comparable for age, 
gender and comorbidities (Table 1). 
Tumor necrotic Factor Alpha (TNF-`) 
Concentration
Serum levels of TNF-a were significantly lower in the mon-
telukast-treated group compared to the control group, 
(P < 0.05), at different study times: before anesthesia; before 
aortic cross clamp; after aortic cross clamp and 24 h after sur-
gery as shown (Fig. 1).
Interleukine 6 (IL6) Concentration
The IL-6 levels were significantly (P < 0.05) lower in mon-
telukast-treated group as compared to the control group at all 
study times (Fig. 2).
Cardiac Troponin I (cTnI)
The concentrations of cTnI were significantly lower in the 
montelukast-treated group compared to the control group at 
the all selected study times, (P < 0.05), (Fig. 3).
Alpha 2 Macroglobulin/Creatinine Ratio (A2M/Cr)
Similarly, the levels of the a2M/Cr ratio were significantly 
(P < 0.05) lower in the montelukast-treated groupy times 
(Fig. 4).
Ejection Fraction (EF)
The EF was significantly higher in the montelukast-treated 
group compared to the Control group after the valve replace-
ment surgery, (P < 0.05), (Fig. 5).
FEV 1 /FVC Ratio
This study showed a non-significant difference in FEV1/FVC 
ratio between the two study groups before the valve replace-
ment surgery. However, the ratio became statistically signifi-
cant, (P < 0.05), in the montelukast-treated group as compared 
to the Control group (Fig. 6).
Correlation Between IL-6 and FEV 1/FVC Ratio
There was a significant negative correlation between the IL-6 
in the bronchial wash and FEV1/FVC ratio, (r = −0.675, 
P < 0.001), for all participants (Fig. 7).
Correlation Between TNF-` and FEV 1/FVC Ratio
Similarly, these was a significant negative correlation between 
the levels of TNF-a in bronchial wash and the FEV 1/FVC ratio, 
(r = −0.708, P < 0.001), (Fig. 8). Table 1.  Demographic characteristics of the participants 
included in this study. Data are represented as mean ± 
standard error of mean. P considered to be significant 
at or below 0.05.
Variable MK group (N = 30) C group (N = 30)
Age/years 48.93 ± 1.68 48.43 ± 1.94
Gender (Male/Female) 13 (43.3%)/17 
(56.7%)
10 (33.3%)/20 
(66.7%)
Body mass index (kg/m2) 27.1 ± 3.9 26.1 ± 2.6
Smoking/non smoking 20/10 21/9
Fasting plasma glucose 
(mmol/l)
5.2 ± 1.7 5.7 ± 2.3
Hypertensive 6 7
Systolic blood pressure 
(mm Hg)
145.5 ± 15 143.7 ± 16.8
Diastolic blood pressure 
(mmHg)
86.8 ± 14 86.5 ± 11.4
Heart rate (beats/min) 85.6 ± 17.5 84.3 ± 12.6
Blood urea (mg/dl) 26.2 ± 8.5 27.5 ± 9
Serum creatinine (mg/dl) 0.78 ± 0.09 0.72 ± 0.1
*significant difference between the two study groups at any time at P equal 
or less than 0.050.
Fig. 1 TNF-` concentration at different study times into two 
groups; montelukast-treated group and control group.
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Fig. 2 IL-6 concentration at different study times into two groups; 
montelukast-treated group and control group.
Fig. 3 CTnI concentration at different study times into two 
groups; montelukast-treated group and control group.
Fig. 4 `2M/Cr concentration at different study times into two 
groups; montelukast-treated group and control group.
Fig. 5 Ejection fraction before and after valve surgery in  
montelukast-treated group and control group.
Fig. 6 FEV 1 /FVC before and after valve surgery in  montelukast- 
treated group and control group.
Discussion
Leukotrienes (LTs) are defined as bioactive proinflamma-
tory molecules that are produced by the 5-lipoxygenase 
pathway from arachidonic acid metabolism in many cells, 
including epithelial cells, fibroblasts, myoblasts, smooth 
muscle cells, basophils, eosinophils, neutrophils, mac-
rophages, and lymphocytes. They play potent inflammatory 
roles in human body response.10 These cytokines, particu-
larly TNF-a, are early regulators of the immune response 
and can induce the release of secondary cytokines, such as 
IL-6 and TNF-a, which provokes neutrophil-mediated 
tissue injury by acting on endothelial cells and other neu-
trophils.10 This study focussed on the anti-inflammatory 
effects of specific cytokines, (TNF-a and IL-6), in amelio-
rating the inflammatory response after elective heart valve 
surgery. Both levels of these cytokines were significantly 
lower, (at all times), in the montelukast-treated groups as 
compared to the Control group, P < 0.05, (Figs 1 and 2). 
This proves the importance of using anti-inflammatory 
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Fig. 7 Correlation between IL-6 and FEV 1/FVC.
Fig. 8 Correlation between TNF-` and FEV 1/FVC.
supplements prior to any invasive heart surgery to reduce 
the inflamatory result and improves the outcomes.11,12
Our findings also indicated that montelukast is able to 
reduce the levels of cTnI (Fig. 3). This is in agreement with the 
previous studies and confirm that montelukast, at high doses, 
might have cardioprotective effects during endotoxemia attrib-
uted to its antioxidant and anti-inflammatory properties.13,14 It is 
also effective in reducing levels of lipopolysaccharides (LPS)- 
induced heart injury and decreasing malondialdehyde (MDA) 
levels, one of LPS-end products.13 Malondialdehyde (MDA) 
also has a potent role in inflammation, and it can increase the 
antioxidant glutathione (GSH) contents in heart tissue.13
Medical treatment with montelukast supplements was 
also beneficial in increasing the percentage of the EF among 
the montelukast-treated group as compareed to the Control 
group (Fig. 5). This is because montelukast has the ability of 
reducing the oxidative stress and apoptosis and providing ben-
eficial effects on myocardial remodeling.15,16
This study also showed significant negative correlations 
between the ratio of FEV1/FVC and the IL6, TNFa (Figs 7 
and 8), respectively. This proves the pulmonary protective 
effects of montelukast in reducing the inflammatory process 
and improving overall lung functions.17,18
Conclusion
This study shows the benefits of using pre-surgical mon-
telukast supplement in ameliorating the inflammatory process 
in patients undergoing cardiopulmonary bypass during valve 
replacement surgery.
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